Rheumatoid arthritis (RA), psoriatic arthritis (PsA), and axial spondyloarthritis (axSpA)
SYRESpyre Therapeutics IncCatalyst overview
Research summary
This catalyst tracks a Phase 2 data readout for SPY072 (SPY002-072) in Rheumatoid arthritis (RA), psoriatic arthritis (PsA), and axial spondyloarthritis (axSpA). The expected timing is based on the latest available company guidance and may change.
03/16/26:- SKYWAY RA enrollment complete; topline data Q3 2026. PsA/axSpA topline data Q4 2026. 05/05/26:- RA sub-study over-enrolled; PoC topline Q3 2026 confirmed. PsA/axSpA topline Q4 2026 reiterated. 06/03/26:- SKYWAY NCT07148414 fully enrolled. RA topline Q3 2026; PsA/axSpA topline Q4 2026 reiterated. 08/04/26:- SKYWAY enrollment complete; RA data September 2026, PsA/axSpA data Q4 2026.
Verification
Confirm timing and program details against the company announcement or filing.